X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple myeloma (187) 187
index medicus (175) 175
daratumumab (160) 160
hematology (119) 119
oncology (113) 113
dexamethasone (110) 110
humans (109) 109
daratumumab monotherapy (97) 97
open-label (90) 90
lenalidomide (84) 84
bortezomib (81) 81
monoclonal antibodies (70) 70
multiple myeloma - drug therapy (67) 67
elotuzumab (55) 55
therapy (55) 55
carfilzomib (52) 52
low-dose dexamethasone (50) 50
cd38 (49) 49
patients (49) 49
immunotherapy (47) 47
antibodies, monoclonal - therapeutic use (42) 42
care and treatment (38) 38
pomalidomide (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
monotherapy (35) 35
male (32) 32
survival (32) 32
aged (31) 31
female (31) 31
middle aged (30) 30
proteasome inhibitors (30) 30
stem-cell transplantation (29) 29
targeting cd38 (29) 29
antitumor-activity (28) 28
cancer (28) 28
antineoplastic agents - therapeutic use (27) 27
combination (26) 26
drug therapy (26) 26
analysis (25) 25
cd38 antigen (25) 25
clinical trials (25) 25
treatment outcome (25) 25
adult (23) 23
lenalidomide plus dexamethasone (23) 23
pharmacology & pharmacy (23) 23
multiple myeloma - pathology (22) 22
multiple myeloma - therapy (22) 22
multiple-myeloma (22) 22
antibodies, monoclonal - administration & dosage (21) 21
diseases (21) 21
multiple myeloma - immunology (21) 21
antibody daratumumab (20) 20
relapse (20) 20
thalidomide - analogs & derivatives (20) 20
transplantation (20) 20
immunology (19) 19
immunomodulation (19) 19
interference (19) 19
medical research (19) 19
abridged index medicus (18) 18
antibodies, monoclonal - adverse effects (18) 18
myeloma (18) 18
review (18) 18
minimal residual disease (17) 17
multiple myeloma - mortality (17) 17
cytotoxicity (16) 16
medicine & public health (16) 16
monoclonal antibody (16) 16
multicenter (16) 16
research (16) 16
aged, 80 and over (15) 15
biological products (15) 15
bone-marrow (15) 15
cells (15) 15
dexamethasone - administration & dosage (15) 15
efficacy (15) 15
phase-2 (15) 15
refractory materials (15) 15
toxicity (15) 15
antibodies (14) 14
cd38 expression (14) 14
health aspects (14) 14
ixazomib (14) 14
monoclonal-antibodies (14) 14
recurrence (14) 14
refractory multiple-myeloma (14) 14
t-cells (14) 14
animals (13) 13
antigens (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
immunotherapy - methods (13) 13
infusion (13) 13
thalidomide - administration & dosage (13) 13
antibodies, monoclonal, humanized - therapeutic use (12) 12
chemotherapy (12) 12
development and progression (12) 12
disease-free survival (12) 12
immunologic factors - therapeutic use (12) 12
medicine, experimental (12) 12
panobinostat (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs.... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Refractory materials | Inhibitors | Interactive systems | Response rates
Journal Article
The Oncologist, ISSN 1083-7159, 03/2018, Volume 23, Issue 3, pp. 279 - 287
Background Daratumumab (a human CD38‐directed monoclonal antibody) and pomalidomide (an immunomodulatory drug) plus dexamethasone are both relatively new... 
Daratumumab | Matching adjusted indirect comparison | Indirect comparison | Multiple myeloma | SURVIVAL | OPEN-LABEL | BORTEZOMIB | PHASE-3 | IMPACT | THERAPY | ONCOLOGY | INDIRECT COMPARISON METHODOLOGY | ANTIBODY DARATUMUMAB | LENALIDOMIDE | CD38 | Academia‐Pharma Intersect | Hematologic Malignancies
Journal Article
by Byun, JM and Yoon, SS and Koh, Y and Kim, I and Jo, J and Park, H and Lee, JO and Lee, J
ANTICANCER RESEARCH, ISSN 0250-7005, 09/2019, Volume 39, Issue 9, pp. 5165 - 5170
Background/Aim: Daratumumab is a promising novel agent for relapsed/refractory multiple myeloma (RRMM). However, there are limited data on its efficacy and... 
real-world | multiple myeloma | DEXAMETHASONE | ONCOLOGY | Daratumumab | relapsed | LENALIDOMIDE | Asian | Refractory materials | Infusion | Toxicity | Immunomodulation | Multiple myeloma | Remission | Survival | Patients | Proteasome inhibitors
Journal Article
BLOOD CANCER JOURNAL, ISSN 2044-5385, 03/2019, Volume 9, Issue 4, pp. 41 - 10
This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple... 
SURVIVAL | DEXAMETHASONE | MULTICENTER | ONCOLOGY | ELOTUZUMAB | LENALIDOMIDE | DARATUMUMAB MONOTHERAPY | OPEN-LABEL | BORTEZOMIB | COMBINATION | HEMATOLOGY | POMALIDOMIDE | Multiple myeloma
Journal Article
Japanese journal of clinical oncology, ISSN 0368-2811, 01/2019, Volume 49, Issue 1, pp. 92 - 95
Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice... 
Refractory | CD38 | Daratumumab | Relapsed | Multiple myeloma | refractory | multiple myeloma | MANAGEMENT | THERAPY | ONCOLOGY | relapsed | IMPROVED SURVIVAL
Journal Article
Experimental Hematology and Oncology, ISSN 2162-3619, 02/2018, Volume 7, Issue 1, pp. 3 - 7
Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy... 
Sustained response | Immune response | Daratumumab | Multiple myeloma | Minimal residual disease | Stringent complete response | Triple refractory | T-cell expansion | Care and treatment | Stem cells | Monoclonal antibodies | Transplantation | B cells | T cells
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 08/2016, Volume 39, Issue 7-8, pp. 482 - 482
Journal Article
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 1, pp. 13 - 29
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues... 
TARGETING CD38 | CD38-TARGETED IMMUNOCHEMOTHERAPY | DEXAMETHASONE | PHASE IB | CLINICAL-EFFICACY | DARATUMUMAB MONOTHERAPY | OPEN-LABEL | ANTITUMOR-ACTIVITY | PATIENTS PTS | HEMATOLOGY | CELL-DEATH
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 11/2016, Volume 39, Issue 11, pp. 742 - 742
Journal Article
Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 22, pp. 2401 - 2409
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring... 
INTERGROUPE FRANCOPHONE | IMPACT | CARFILZOMIB | RESPONSE CRITERIA | T(11/14)(Q13,Q32) | CHRONIC LYMPHOCYTIC-LEUKEMIA | DARATUMUMAB MONOTHERAPY | OPEN-LABEL | BORTEZOMIB | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Life Sciences | Cancer
Journal Article
Journal Article